Industry Explorers Blaze On

  1. Why Counterfeit And Substandard Antibiotics Matter To The Pharma Industry 8/1/2023

    Due to a lack of regulation and enforcement in such regions, as well as a lack of access to quality healthcare, the antibiotic “gray market” is fertile ground for exploitation.

  2. Novo Nordisk Returns To Growth, With Growing Pains 8/1/2023

    Novo Nordisk’s return to growth is largely due to an explosion of demand for its anti-obesity products. However, challenges with supply and insurance coverage persist.

  3. How Can Drug Developers Work Together With The FDA To Maximize The Value Of A Clinical Trial Protocol? 8/1/2023

    See the answer from Mitchell Katz, PhD, SVP, global clinical operations, at Kyowa Kirin.

  4. Companies To Watch: Ventoux Biosciences 8/1/2023

    Why Ventoux Biosciences is pursuing drug treatments for all sufferers of Dupuytren’s and other fibroproliferative diseases.

  5. Adjusting Industry Expectations of Investigators: Why It Matters 8/1/2023

    Considering less than 3% of physicians engage in clinical research, with a high percentage leaving after just one trial, what can be done to get more investigators interested in participating — and staying involved?

  6. Understanding Data Collection And Management In DCTs 8/1/2023

    For decentralized clinical trials (DCTs), it is important to specify the risks up front and determine if — and how — this approach can be applied to each protocol. Further, from a data collection and management standpoint, there is plenty to consider in terms of data flow management through multiple sources and systems.

  7. Cost Of Quality: Worth Every Cent In Biopharma Manufacturing 8/1/2023

    In many cases, management has viewed budget items for improving systems, equipment, employee education, and qualifying secondary suppliers and their materials, as “nice to haves” instead of necessities. As a result, these quality system areas were not invested in as much as is necessary to ensure optimal bottom-line results.

  8. Going European — Affimed's American CBO 8/1/2023

    Taking the CBO position at Affimed offered Denise Mueller a way to apply her skills in an international biotech startup environment, where she could help shape the company’s innovative approach to cancer immunotherapy.

  9. Market Dislocations And Their Impact On Life Sciences Debt Financing 8/1/2023

    : Life sciences companies seeking debt financing or facing challenges in their existing debt financing now face a very different financing environment. But there are some steps you can take.

  10. Given The Increase In Size Of The Industry And The Challenge Of Fundraising, Are There Other Ways To Think About Raising Capital? 7/3/2023

    See the answer from Dennis Purcell, founder and senior advisor at Aisling Capital.